New treatment slows Alzheimer's progression in monkeys, researchers claim - Fox News

"Our findings illustrate that this therapy is an effective way of manipulating the immune system to slow neurodegeneration," Akash Patel, MS, an assistant research scientist in the Center for Cognitive Neurology at NYU Langone Health, said in a news release posted to EurekAlert.org?

WHO SHOULD TAKE BIOGEN'S ALZHEIMER'S DRUG.

FDA OK'S BIOGEN'S ALZHEIMER'S DRUG: WHAT IS ACCELERATED APPROVAL.

The Centers for Disease Control and Prevention (CDC) pins Alzheimer's disease as the sixth leading cause of death.

While the disease still has no cure, Biogen's drug aducanumab recently won a controversial FDA authorization in the fight against Alzheimer's, though experts say the drug likely wouldn't bring much benefit to patients with severe courses of disease.

The squirrel monkeys were said to be ideal for studying Alzheimer's due to a similar progression of neurodegeneration associated with aging, as seen in humans.

She warned that only animals with significant signs of neurodegeneration were studied, and further studies will involve younger animals to explore the drug's efficacy in earlier courses in disease